Finance

Lists
RHHVF:OTCMKTS
Roche Holding AG Genussscheine
USD 427,38
-0,12%
(-0,50) 1D
6 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RHHVF...
Open
USD 423,04
High
USD 427,45
Low
USD 417,04
Mkt. cap
339,07 mjd
Avg. vol.
5,23 k
Volume
677,00
52-wk high
USD 490,33
52-wk low
USD 318,81
Beta
0,51
Shares outstanding
702,56 m
No. of employees
113 k
Open
USD 423,04
High
USD 427,45
Low
USD 417,04
Mkt. cap
339,07 mjd
Avg. vol.
5,23 k
Volume
677,00
52-wk high
USD 490,33
52-wk low
USD 318,81
Beta
0,51
Shares outstanding
702,56 m
No. of employees
113 k
News stories
From web sources and news partners
Profile
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76. The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights, with Swiss pharma firm Novartis owning a further third of its shares until 2021. F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations. Wikipedia
About Roche Holding AG Genussscheine
CEOThomas Schinecker
Employees113 k
Founded01 Okt. 1896
HeadquartersBasel, Basel City, Switserland
SectorPharmaceutical industry
Websiteroche.com
Previous reportsAll values in CHF
Loading Previous Earnings...
Revenue
Net income
All values in CHF
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
15,75 mjd
15,75 mjd
15,73 mjd
15,73 mjd
Cost of goods sold
4,21 mjd
4,21 mjd
3,93 mjd
3,93 mjd
Cost of revenue
4,21 mjd
4,21 mjd
3,93 mjd
3,93 mjd
Research and development expenses
3,15 mjd
3,15 mjd
2,99 mjd
2,99 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,59 mjd
3,59 mjd
3,22 mjd
3,22 mjd
Operating expense
6,82 mjd
6,82 mjd
6,11 mjd
6,11 mjd
Total operating expenses
11,03 mjd
11,03 mjd
10,03 mjd
10,03 mjd
Operating income
4,72 mjd
4,72 mjd
5,69 mjd
5,69 mjd
Other non operating income
-10,00 m
-10,00 m
-15,00 m
-15,00 m
EBT including unusual items
3,69 mjd
3,69 mjd
4,49 mjd
4,49 mjd
EBT excluding unusual items
4,37 mjd
4,37 mjd
5,38 mjd
5,38 mjd
Income tax expense
709,00 m
709,00 m
824,00 m
824,00 m
Effective tax rate
19,20%
19,20%
18,37%
18,37%
Other operating expenses
77,50 m
77,50 m
-99,00 m
-99,00 m
Net income
2,74 mjd
2,74 mjd
3,44 mjd
3,44 mjd
Net profit margin
17,36%
17,36%
21,85%
21,85%
Earnings per share
-
-
-
-
Interest and investment income
45,00 m
45,00 m
43,50 m
43,50 m
Interest expense
-289,50 m
-289,50 m
-282,00 m
-282,00 m
Net interest expenses
-244,50 m
-244,50 m
-238,50 m
-238,50 m
Depreciation and amortization charges
-
-
-
-
EBITDA
5,50 mjd
5,50 mjd
6,48 mjd
6,48 mjd
Gain or loss from assets sale
-21,50 m
-21,50 m
-2,50 m
-2,50 m
AI content may include mistakes. Learn more
Google-programme